Maxigen Biotech Inc. (1783.TW)
Taiwan · TWD · Healthcare · Medical Instruments & Supplies
NT$36.30 (-0.27%) as of
Key statistics
- Market cap
- 3.26B
- P/E (TTM)
- 11.24
- EPS (TTM)
- 3.23
- Dividend yield
- 5.49%
- 52-week range
- 35.85 – 48.30
- Beta
- 0.36
- Revenue (TTM)
- 837.44M
- Profit margin
- 34.77%
- Volume
- 36.55k
About Maxigen Biotech Inc.
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, electronic instructions for use, and medical aesthetics, as well as engages in collagen purification activities. It also offers ophthalmic viscoelastic under the PreviscAid, ViscAid, and BiVisc brands; intra-articular injections under the ArtiBest and ArtiAid brands; synthetic bone grafts under the BestAid, GingivAid, FormaGraft, and Foramic brands; and dermal filler injections under the Formaderm brand. In addition, the company provides collagen based regenerative matrixes comprising HealiAid, a collagen wound dressing; NasoAid, an intranasal splint; and FormaAid, a collagen membrane. Maxigen Biotech Inc. was incorporated in 1998 and is headquartered in Taoyuan City, Taiwan.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Headquarters
- Taoyuan City, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.